Category: Mergers and Acquisitions

August 10, 2023

Regeneron Pharmaceuticals and Decibel Therapeutics announced a definitive agreement on August 9, 2023, for the acquisition of Decibel by Regeneron at $4 per share of Decibel common stock payable in cash at closing. “We at Decibel are deeply committed to […]

August 4, 2023

On Aug. 1, 2023, US-based iTolerance, an early-stage regenerative medicine company, and Lithuania-based Northway Biotech, a contract development and manufacturing organization, announced that they have entered into an agreement for the manufacturing of Streptavidin-FasL (SA-FasL) fusion protein, an important component […]

July 27, 2023

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, and BioSight Ltd., a pharmaceutical company developing therapeutics for hematological malignancies and disorders, entered into a definitive merger agreement pursuant to which Ayala will combine with Biosight in an all-stock transaction. The combined […]

July 20, 2023

Novartis has acquired DTx Pharma, a US-based, preclinical-stage biotechnology company, for an upfront payment of $500 million plus additional payments of up to $500 million, dependent on the completion of pre-specified milestones, the companies announced in their respective July 17, […]

July 17, 2023

Vector Laboratories announced the acquisition of Quanta BioDesign on July 17, 2023, which further expands the former’s portfolio of bioconjugation linkers and dyes, as well as its manufacturing sector, according to the press release. “This acquisition is valuable because it […]

July 14, 2023

Frequency has had a rocky year, recently undergoing a restructuring after an experimental drug for hearing loss failed to meet its goal in a clinical trial. The company shut down the program and laid off about half of its workforce […]

July 13, 2023

Applied DNA Sciences, Inc. a company involved with PCR-based DNA technologies, acquired Spindle Biotech Inc., an early-stage, private biotech company developing next-generation RNA manufacturing technologies. The acquisition leverages the company’s LinearDNA platform that enables efficient chemical modification of DNA templates […]

June 12, 2023

Novartis has agreed to acquire Chinook Therapeutics for as much as $3.5 billion, taking a chance that a pair of kidney disease drugs the biotechnology company has developed will succeed in late-stage testing. Under the deal announced Monday, Novartis will […]

May 18, 2023

Revvity, a provider of health sciences services, entered a new license agreement with AstraZeneca for the technology underlying its Pin-point base editing system, a next-generation modular gene editing platform with a strong safety profile. The Pin-point system and the underlying […]

May 9, 2023

Gilead Sciences, Inc. has acquired all outstanding shares of XinThera, a privately held biotech company in San Diego. The acquisition adds clinical development pipeline assets for well-validated targets in oncology and inflammation. Through the acquisition, Gilead gains rights to a […]

May 5, 2023

Moderna, Inc., a provider of messenger RNA (mRNA) therapeutics and vaccines, entered into a long-term agreement with Ontario-based Novocol Pharma, a sterile injectable contract development and manufacturing organization (CDMO), to perform aseptic fill-finish, labelling and packaging of mRNA respiratory vaccines […]

May 1, 2023

Japanese drugmaker Astellas Pharma on Sunday agreed to acquire Iveric Bio for about $5.9 billion, betting that a medicine the biotechnology company has developed for a common type of vision loss can help it build an eye drug business. Astellas […]

April 28, 2023

Adaptive Biotechnologies Corporation announced on April 12, 2023 that it has begun a translational collaboration with Takeda. Adaptive Biotechnologies will use its clonoSEQ Assay to assess minimal residue disease (MRD) to start with the development and commercialization of Takeda’s pipeline […]

April 18, 2023

Merck and Prometheus Biosciences, a clinical-stage biotechnology company specializing in immune-mediated diseases, announced an acquisition agreement on April 16, 2023. Merck will acquire all outstanding shares of the company for $200 per share, a total approximate equity valuation of approximately […]

April 3, 2023

Armed with cash earned from sales of the COVID-19 vaccine it developed with Pfizer, BioNTech has been investing in cancer drug research and development — its primary focus prior to the pandemic. While BioNTech specializes in messenger RNA, it also […]

March 31, 2023

Sartorius, a Germany-based manufacturer and supplier to the biopharmaceutical industry, is acquiring France’s Polyplus in a $2.6 billion acquisition meant to expand the company’s role as partner to gene and cell therapy developers. Under a deal announced Friday, Sartorius will […]

March 30, 2023

Junshi Biosciences Co., Ltd and Rxilient Biotech entered into a collaboration for the development and commercialization of the anti-PD-1 monoclonal antibody drug, toripalimab, through joint venture in 9 Southeast Asian nations, including Thailand, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the […]

March 28, 2023

Regeneron became one of biotech’s most valuable companies through its success making antibody drugs. Its flagship technology, a way of testing potential medicines on genetically modified mice, has helped it unearth antibody treatments for eye diseases, autoimmune conditions, rare disorders […]

March 24, 2023

Curia announced on March 23, 2023 that it is collaborating with Corning to expand and accelerate continuous-flow development and manufacturing programs for the chemical and biopharmaceutical industries globally. The collaboration marks the first global installation of Corning’s G1 production system […]

March 24, 2023

Harm Reduction Therapeutics, a 501(c)(3) non-profit pharmaceutical company whose mission is to prevent opioid overdose deaths, signed a commercial supply agreement with Catalent for the manufacture Harm Reduction Therapeutics’ naloxone nasal spray, RiVive (3.0 mg), for the emergency treatment of […]